The New Dimensions of Warfarin Prophylaxis

1. Front Matter

   Pages i-ix

   PDF

2. The Scope of thromboembolism

   1. The Scope of Thromboembolism

      • Stanford Wessler

      Pages 1-2

3. Vitamin K-Dependent Proteins

   1. The Biochemical Basis of Warfarin Therapy

      • J. W. Suttie

      Pages 3-16

   2. Warfarin and the Biochemistry of the Vitamin K Dependent Proteins

      • Edwin G. Bovill, Kenneth G. Mann

      Pages 17-46

   3. Anticoagulation Proteins C and S

      • Charles T. Esmon, Silvana Vigano-D’Angelo, Armando D’Angelo, Philip C. Comp

      Pages 47-54

   4. Warfarin and Bone: Implications for Rational Strategies to Selectively Antagonize the Action of Vitamin K in Target Tissues

      • Paul A. Price

      Pages 55-66

   5. Human Genes for Factor IX and other Vitamin K Dependent Blood Proteins

      • Kotoku Kurachi, Shi-Han Chen

      Pages 67-81

4. The Prothrombin Time

   1. Tissue Factor and the Initiation of Blood Coagulation

      • Yale Nemerson

      Pages 83-94

   2. INR — Calibration of the Therapeutic Range

      • Leon Poller

      Pages 95-112

   3. Cold-Promoted Activation of Factor VII and Shortening of the Prothrombin Time

      • Harvey R. Gralnick, Olga J. Wilson

      Pages 113-129

   4. Immunologic Aspects of Vessel Injury and Thrombosis

      • Carl G. Becker

      Pages 131-147

   5. What’s the Dose?

      • Stanford Wessler

      Pages 149-152

5. Venous Thromboembolism — Primary Prophylaxis

   1. Venous Thromboembolism in Moderate Risk Patients

      • Edward Genton

      Pages 153-158

   2. Two-Step Warfarin Therapy for the Prophylaxis of Venous Thrombosis After Elective Surgery

      • Victor J. Mader, Charles W. Francis

      Pages 159-163

   3. Prevention of Venous Thromboembolism in High-Risk Patients by Prophylactic Administration of Oral Anticoagulants

      • Edwin W. Salzman

      Pages 165-174

   4. Genetic Coagulation Defects

      • Ewa Marciniak

      Pages 175-186

6. Venous Thromboembolism — Secondary Prophylaxis

   1. Treatment of First Episode of Venous Thrombosis

      • J. Hirsh, M. Levine, R. Hull

      Pages 187-193

   2. Management of Recurrent Venous Thromboembolism

      • Kenneth M. Moser

      Pages 195-204

7. Special Issues

   1. Warfarin Metabolism and Drug-Drug Interactions

      • Robert A. O’Reilly

      Pages 205-212

   2. Improving the Benefit/Risk Ratio

      • Stanford Wessler

      Pages 213-216

The International Symposium on The New Dimensions of Warfarin Prophylaxis held on October 16-18, 1986 in New York City was conceived as a forum to bring together physicians and other scientists knowledgeable about the pharmacological effects of warfarin on the hemostatic mechanism and the clinical usefulness of this compound in the prevention of thromboembolic phenomena. The coumarin compounds have commanded a striking breadth of interest among members of the biomedical research community for almost one-half century. Aspects of its effects on the vitamin K-dependent proteins, on the laboratory recognition of the drug's pharmacologic action and its use as a therapeutic agent in a variety of disease states have been actively studied with increasing intensity in the past several decades. Thus, the present state of these studies seemed to be a timely subject for discussion, not only to gather together in one place representative samples of the myriad of data on warfarin, but also to underscore the ever increasing necessity for communication between basic research and clinical practice. The content and organization of this monograph reflect the scope and importance of warfarin prophylaxis. One of the unique aspects of this publication is that it spells out in one place the warfarin story from molecular biology through clinical trials to future directions of research and patient care.

• atrial fibrillation
• cardiovascular
• embolism
• heart
• stroke
• vascular disease

• New York University School of Medicine, New York, USA

  Stanford Wessler

• Cornell University Medical College, New York, USA

  Carl G. Becker

• Mt. Sinai School of Medicine of the City University of New York, New York, USA

  Yale Nemerson

Policies and ethics